Main Menu

Novel Engineered RBD Antigens: Elevating Coronavirus Vaccine Efficiency and Efficacy. These groundbreaking antigens, derived from the spike protein's receptor-binding domain, are meticulously designed through a computational pipeline, resulting in superior attributes. They increase protein yield sevenfold, ensuring efficient large-scale manufacturing. With elevated thermal stability and a tenfold boost in antibody production, these antigens present a significant stride towards potent and globally accessible coronavirus vaccines.

This technology involves the creation of monoclonal antibodies through hybridoma technology, specifically, hybridomas 3B6, 14B7, 2D3, 2G4, 1G3, 6H3, 6C5, and 3D12, which exhibit a high degree of reactivity with Bacillus anthracis protective antigen (PA). These monoclonal antibodies have shown great promise in the field of anthrax detection and diagnosis. Their exceptional specificity for Bacillus anthracis PA suggests their potential application in diagnostic devices.

Monoclonal antibodies produced by hybridomas IE5, IE9, and 13B3 are specific for the Bacillus anthracis PA20 fragment. These antibodies hold significant potential for rapid and precise Bacillus anthracis diagnosis in clinical and environmental samples. They can be employed in various diagnostic assays, offering a valuable tool for public health and biosecurity applications. Rigorous testing and validation are essential before their integration into diagnostic devices.

Traf3ip2-/- C57/BL6 mice are a genetically modified mouse model in which the Traf3ip2 gene, responsible for encoding the CIKS adaptor protein essential for IL-17 cytokine signaling, has been disrupted. These mice offer a robust platform for research in autoimmune and inflammatory diseases, as well as potential applications in cancer studies. By eliminating IL-17 signaling and cross-interactions with other pathways, they provide a unique opportunity for drug discovery and proof-of-principle studies, shedding light on disease mechanisms and therapeutic development.

Trispecific and trivalent binding proteins represent a breakthrough in the battle against HIV infection. These specialized proteins are engineered with four polypeptide chains forming three antigen binding sites, enabling precise targeting of HIV target proteins. Addressing the formidable challenges of HIV treatment, including the virus's high mutation rate and the persistence of viral reservoirs, these binding proteins offer a potential solution to breakthrough infections.

Engineered Influenza Neuraminidase Antigens represent a cutting-edge approach to revolutionize Influenza vaccine development. This technology harnesses the sequences of neuraminidase (NA) proteins, pivotal components of the Influenza virus, to create stabilized tetramers for multiple NA subtypes. By identifying specific mutations, the technology enables the control of NA protein conformations, particularly closed states, which significantly enhances their stability.

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and the University of Maryland have unveiled a groundbreaking discovery, revealing the formation of a recombinant heterodimer known as p40-CD5L by combining two known proteins, p40 and CD5L. This heterodimer's significance lies in its ability to stimulate the production of interleukin-4 (IL-4) and interleukin-10 (IL-10) by T cells, which holds great promise for addressing conditions such as allergies, asthma, and tumor immunology.

The technology at hand represents a pivotal advancement in the early detection of Type 1 Diabetes (T1D) and the associated autoimmune processes. By utilizing electrochemiluminescence (ECL)-based assays, it enables the precise measurement of diabetes-associated antibodies, particularly Insulin Autoantibodies (IAA) in non-obese diabetic (NOD) mice and anti-insulin antibodies (IA) in individuals with Type 1 diabetes. Notably, these assays are non-radioactive, ensuring safety and compliance, while also offering exceptional reproducibility and efficiency.

This technology presents an innovative approach to the treatment of Graft Versus Host Disease (GvHD) by harnessing the therapeutic potential of Pregnancy Specific Glycoproteins (PSG1 and PSG9). The method involves a novel administration technique for these glycoproteins, which had not been previously disclosed prior to the patent application. The technology holds promise in addressing the challenges associated with GvHD treatment, potentially offering new avenues for improving patient outcomes in this complex medical condition.

This technology presents a groundbreaking approach to developing a vaccine for Respiratory Syncytial Virus (RSV), a major cause of severe pediatric respiratory illness. The method involves the creation of a live attenuated RSV vaccine candidate by removing the M2-2 protein, resulting in decreased viral replication. Surprisingly, this modification induces a stronger immune response. The vaccine, derived from LID M2-2 with minor mutations, effectively separates viral replication from immunogenicity.